acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

General

 8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is actively

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction In 24-Hour Ambulatory Systolic Blood Pressure In Hypertensive Pacemaker Patients Treated With AVIM Therapy For Over 3 Years - Orchestra BioMed Hldgs (NASDAQ:OBIO)

Happy Mohamed

Medtronic

Orchestra BioMed Hldgs


	8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study
	Orchestra BioMed is actively

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction In 24-Hour Ambulatory Systolic Blood Pressure In Hypertensive Pacemaker Patients Treated With AVIM Therapy For Over 3 Years

Comments